Current approaches to the treatment of pulmonary arterial hypertension: prospects for disease modification and therapeutic strategies
https://doi.org/10.31549/2542-1174-2025-9-1-124-135
Abstract
Pulmonary arterial hypertension (PAH) is a progressive disease accompanied by proliferative remodeling of the pulmonary arteries. Despite the obvious advances in its treatment that have occurred recently, the mortality associated with PAH remains high. We present a review of modern Russian and foreign literature devoted to the problem of PAH and the search for methods to solve it. The following resources were used in our review: Russian Science Citation Index, Best Evidence, Scopus, Elsevier, PubMed, Clinical Evidence, Cochrane Library. Therapeutic strategies that have a potency for modification of the disease are presented. Among the novel drugs, two seem to be particularly promising since they have potent disease-modifying properties: sotatercept, which targets the TGF-β superfamily pathway, and seralutinib, an inhaled PDGFR inhibitor. Although sotatercept has demonstrated great efficacy, seralutinib has a potential for the combined therapy use.
About the Authors
L. D. Khidirova
Novosibirsk State Medical University
Russian Federation
Russian Federation
Khidirova Lyudmila D. – Dr. Sci. (Med.), Professor, Department of Pharmacology, Clinical Pharmacology and Evidence-based Medicine
52, Krasny prosp., Novosibirsk, 630091
V. N. Tyupina
Novosibirsk Regional Clinical Cardiological Dispensary
Russian Federation
Russian Federation
Tyupina Victoria N. – Head, Outpatient Department
Novosibirsk
References
1. Simonneau G., Montani D., Celermajer D.S. et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur. Respir. J. 2019;53(1):1801913. DOI: 10.1183/13993003.01913-2018.
2. Rosenkrantz S., Diller G.P., Dumitrescu D. et al. Hemodynamic definition of pulmonary hypertension: Commentary on the proposed change by the 6th World Symposium on Pulmonary Hypertension. Dtsch. Med. Wochenschr. 2019;144(19):1367-1372. DOI: 10.1055/a-0918-3772.
3. Chazova I.E., Arkhipova O.A., Martynyuk T.V. et al. Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry. Therapeutic Archive. 2019;91(1):24-31. DOI: 10.26442/004 03660.2019.01.000024. (In Russ.)
4. Chazova I.E., Martynyuk T.V., Valieva Z.S. et al. Eurasian clinical guidelines on diagnosis and treatment of pulmonary hypertension. Eurasian Heart Journal. 2020;(1):78-122. DOI: 10.38109/2225-1685-2020-1-78-122. (In Russ.)
5. Khidirova L., Tyupina L. Current aspects of the management of patients with idiopathic pulmonary arterial hypertension. Vrach. 2024;35(9):44-48. DOI: 10.29296/25877305-2024-09-08. (In Russ.)
6. Galiè N., Humbert M., Vachiery J. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Russian Journal of Cardiology. 2016;(5):5-64. DOI: 10.15829/1560-4071-2016-5-5- 64. (In Russ.)
7. Humbert M., Kovacs G., Hoeper M.M. et al. 2022 ESC/ ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur. Heart J. 2022;43(38):3618–3731. DOI: 10.1093/eurheartj/ehac237.
8. Lyapina I.N., Zvereva T.N., Martynyuk T.V. Combination therapy of newly diagnosed intermediaterisk pulmonary arterial hypertension: A review. Consilium Medicum. 2022;24(10):688-695. DOI: 10.26442/20751753.2022.10.2018. (In Russ.)
9. Sotatercept tied to disease modification in pulmonary arterial hypertension// Medscape. Dec 9, 2024. URL: https://www.medscape.com/viewarticle/996507 (accessed 09.12.2024)
10. Montani D., Günther S., Dorfmüller P. et al. Pulmonary arterial hypertension. Orphanet J. Rare Dis. 2013;8:97. DOI: 10.1186/1750-1172-8-97.
11. Waxman A.B., Systrom D.M., Manimaran S. et al. SPECTRA phase 2b study: Impact of sotatercept on exercise tolerance and right ventricular function in pulmonary arterial hypertension. Circ. Heart Fail. 2024; 17(5):e011227. DOI: 10.1161/CIRCHEARTFAILURE.123.011227.
12. Franz R.P., Benza R.L., Channic R.N. et al. TORREY, a phase 2 study to evaluate efficacy and safety of inhaled seralutinib for the treatment of arterial hypotension. Pulm. Circ. 2021;11(4):20458940211057071. DOI: 10.1177/20458940211057071.
13. Zamanian R., Rahagi F.N., Howard L.S. and others. Seralutinib improves the volume distribution of pulmonary artery blood vessels in pulmonary arterial hypertension (PAH): results of the 2nd phase of the TORREY imaging study. URL: https://www.gossahttp://merbio.com/wp-content/uploads/ERS%202023%20%20FRI%20final.pdf%20(accessed%2023.12.2024)
14. Humbert M., McLaughlin V., Gibbs J.S.R. et al. Sotatercept for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 2021;384(13): 1204-1215. DOI: 10.1056/NEJMoa2024277.
15. Souza R., Badesch D.B., Ghofrani H.A. et al. Effects of sotatercept on hemodynamics and right heart function: analysis of the STELLAR trial. Eur. Resp. J. 2023;62(3):2301107. DOI: 10.1183/13993003.01107-2023.
16. Joshi S.R., Liu J., Bloom T. et al. The sotatercept analogue suppresses inflammation in order to reverse experimental pulmonary arterial hypertension// Sci. Rep. 2022;12:7803 DOI: 10.1038/s41598-022-11435-x.
17. Sotatercept endorsed for PAH by ICER// Medscape, Dec 10, 2024. URL: https://www.medscape.com/viewarticle/sotatercept-endorsed-pah-icer-2023a1000uef?form=fpf (accessed 10.12.2024).
Review
For citations:
Khidirova L.D., Tyupina V.N. Current approaches to the treatment of pulmonary arterial hypertension: prospects for disease modification and therapeutic strategies. Journal of Siberian Medical Sciences. 2025;(1):124-135. (In Russ.) https://doi.org/10.31549/2542-1174-2025-9-1-124-135
Views:
83
Email this article 